NeuBase Therapeutics, Inc. reported earnings results for the first quarter ended December 31, 2021. For the first quarter, the company reported net loss was USD 7.73 million compared to USD 4.07 million a year ago. Basic loss per share from continuing operations was USD 0.24 compared to USD 0.18 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.378 USD | -3.20% |
|
-.--% | -48.93% |
Jun. 27 | NeuBase Therapeutics, Inc. Announces Board Resignations | CI |
May. 29 | NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- O7P Stock
- NBSE Stock
- News NeuBase Therapeutics, Inc.
- NeuBase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021